5-panel drug test — complete buyer's guide

The urine cup is the default 5-panel format for a reason. Collection happens directly into the vessel that runs the test, which means there is no specimen transfer step, no separate pour into a test device, and one fewer place for chain-of-custody documentation to break. For DOT-regulated programs, the urine cup is the format your collectors are already trained on under 49 CFR Part 40 procedures.

Integrated temperature strips on modern 5-panel cups give collectors an immediate adulteration check — a specimen outside the 90–100°F range within four minutes of voiding is presumptively invalid under DOT standards. The cup also supports observed collections when the testing protocol requires them (return-to-duty, follow-up testing after a verified positive).

The unit cost premium over dip cards is real but small at volume. For most non-budget-constrained programs, the operational simplicity of the cup format is worth the few cents per test. The bathroom logistics — privacy, water shutoff, blue dye — are real but well-documented; SAMHSA and DOT both publish detailed collection-site setup guidance.

Dip cards are the answer when budget pressure is real and DOT regulation is not. At volume, the per-test savings versus a cup add up — a sober-living network testing 200 residents monthly can save thousands per year switching from cups to dip cards without changing the analyte scope.

The tradeoff is operational. A dip card workflow requires a separate collection container (paper cup, sterile specimen cup, etc.), which adds a transfer step and a second item to document on the chain of custody. Dip cards generally do not have integrated temperature strips, so adulteration screening requires a separate temperature-strip cup or a thermometer reading within the four-minute window.

For DOT testing, dip cards are not appropriate as the primary collection device because 49 CFR Part 40 specifies the specimen container and chain-of-custody form requirements. Some programs use dip cards as a quick presumptive read in parallel with a DOT-compliant split-specimen send-out, but that is a workflow choice and not a substitute for the federally required process.

Oral fluid testing closed a long-standing gap in workplace drug testing: how to run an observed collection without sending a same-gender monitor into a bathroom. The collector simply observes the donor place the swab in their mouth, wait the absorption time, and seal it. Substitution and dilution become essentially impossible.

DOT's 2023 rule update to 49 CFR Part 40 added oral fluid as a permitted specimen type for DOT-regulated programs, alongside urine. The rule requires a SAMHSA-certified oral-fluid collection device and lab confirmation by an HHS-certified laboratory for non-negatives. SAMHSA publishes Mandatory Guidelines for Oral Fluid that lay out cutoff levels and procedures.

The detection-window tradeoff cuts both ways. Oral fluid catches very recent use (last 24–48 hours for most drugs, slightly longer for some) but misses the longer-window THC detection that urine provides. For post-accident testing where the question is 'were they impaired at the time of the incident?', oral fluid is better — urine THC can stay positive for weeks after a chronic user's last use, which is not useful for that question. For pre-employment, urine remains the higher-yield specimen.